Brooklyn ImmunoTherapeutics Inc News - BTX

BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways...

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois...

BioTime Warrants to Expire on October 1, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its...

BioTime met à jour le calendrier de distribution des actions AgeX à ses actionnaires

Approbations réglementaires en cours ; la nouvelle date d’enregistrement sera définie prochainement BioTime, Inc. (NYSE American : BTX...

BioTime aktualisiert Zeitplan für die Verteilung der AgeX-Aktien an BioTime-Aktionäre

Behördliche Genehmigungen in Bearbeitung; neuer Stichtag steht kurz bevor BioTime, Inc. (NYSE American: BTX), ein auf degenerative...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer

Former Co-CEO Adi Mohanty to Aid in Transition and Continue to Serve on the Boards of Asterias and OncoCyte Former Co-CEO Michael West...

BioTime fornisce un aggiornamento sulla tempistica della distribuzione delle azioni di AgeX agli azionisti di BioTime

Gli iter per il rilascio delle autorizzazioni necessarie da parte degli enti normativi competenti sono attualmente in corso; a breve verrà...

BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

Regulatory Approvals In-Process; New Record Date to be Set Shortly BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology...

BioTime clôture une transaction de vente d'actions AgeX de 43,2 millions USD avec Juvenescence

Le produit fournit suffisamment de capital pour financer BioTime à travers des étapes majeures pour les programmes actuels, y compris les...

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Erlös stellt BioTime ausreichend Kapital für die Finanzierung wichtiger Meilensteine aktueller Programme zur Verfügung, einschließlich...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia® and OpRegen® key...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences

Adi Mohanty to participate in panel discussion at the Annual B. Riley FBR Healthcare Conference Adi Mohanty and Russell Skibsted to...

AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance

Technology supports Company’s strategy for off-the-shelf (allogeneic) cell-based regenerative medicine products through the use of the HLA-G...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BTX News

BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways...

BioTime Warrants to Expire on October 1, 2018

BioTime met à jour le calendrier de distribution des actions AgeX à ses actionnaires

BioTime aktualisiert Zeitplan für die Verteilung der AgeX-Aktien an BioTime-Aktionäre

Current Report Filing (8-k)

BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer

BioTime fornisce un aggiornamento sulla tempistica della distribuzione delle azioni di AgeX agli azionisti di BioTime

BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

BioTime clôture une transaction de vente d'actions AgeX de 43,2 millions USD avec Juvenescence

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Statement of Changes in Beneficial Ownership (4)

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

Current Report Filing (8-k)

BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences

AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance

BTX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX) News

Brooklyn ImmunoTherapeutics Inc (BTX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BTX News

BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways...

BioTime Warrants to Expire on October 1, 2018

BioTime met à jour le calendrier de distribution des actions AgeX à ses actionnaires

BioTime aktualisiert Zeitplan für die Verteilung der AgeX-Aktien an BioTime-Aktionäre

Current Report Filing (8-k)

BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer

BioTime fornisce un aggiornamento sulla tempistica della distribuzione delle azioni di AgeX agli azionisti di BioTime

BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

BioTime clôture une transaction de vente d'actions AgeX de 43,2 millions USD avec Juvenescence

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Statement of Changes in Beneficial Ownership (4)

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

Current Report Filing (8-k)

BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences

AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance

BTX Discussion

Your Recent History